Keratolytics: Salicylic Acid, Urea, Benzoyl Peroxide, Tretinoin & Podophyllin

Keratolytics: salicylic acid, urea, benzoyl peroxide, tretinoin, propylene glycol and podophyllin

Keratolytics are topical agents that loosen, soften or remove excess keratin from the stratum corneum. They are used when abnormal scaling, follicular plugging, callus, corn, wart or hyperkeratotic plaque prevents normal shedding or blocks penetration of another treatment. The supplied teaching deck describes salicylic acid, propylene glycol, urea, benzoyl peroxide, tretinoin and podophyllin resin; this lesson preserves those points and expands them with current prescribing, safety and emergency-care principles.

Learning objectives

• Explain the epidermal barrier, keratinisation and why hyperkeratosis develops.
• Classify keratolytics according to their mechanism and clinical role.
• Select appropriate concentrations and formulations for acne, psoriasis, seborrhoeic dermatitis, ichthyosis, keratosis pilaris, calluses, corns and warts.
• Describe mechanism, adult and paediatric use, application technique, contraindications, adverse effects, interactions and monitoring for the major agents.
• Recognise salicylism, chemical burns, severe irritant dermatitis, allergic reactions and podophyllin toxicity as emergencies.
• Combine a keratolytic safely with an anti-inflammatory or antimicrobial treatment without damaging the skin barrier.

1. Skin science behind keratolytic therapy

The stratum corneum is a controlled barrier

The epidermis continually produces keratinocytes. As they move outward, they lose their nuclei, become flattened corneocytes and are embedded in a lipid-rich matrix of ceramides, cholesterol and fatty acids. Corneodesmosomes hold adjacent corneocytes together until controlled enzymatic desquamation releases them. Natural moisturising factors, including amino acids, lactate and urea, hold water inside the stratum corneum.

In a healthy person this process is balanced: cells are produced, compacted, hydrated and shed at a predictable rate. In hyperkeratotic disease, production is accelerated, shedding is defective, follicular openings become plugged, or the barrier becomes excessively dry. The result is a thick, rough, scaly or fissured surface. Keratolytics work mainly by weakening the bonds or matrix between corneocytes, increasing water content, or normalising the abnormal follicular process.

Hyperkeratosis is not one diagnosis

Why removing scale helps another medicine

A thick stratum corneum can act like a roof over active disease. Salicylic acid or urea can thin the roof and increase penetration of a topical corticosteroid or antifungal. The same principle can cause harm: applying a potent steroid immediately after aggressive keratolysis, covering a large area with occlusion, or combining several irritants may produce erosions and excessive systemic absorption.

2. Classification of keratolytic and keratolytic-like agents

3. Salicylic acid

Mechanism of action

Salicylic acid is a beta-hydroxy acid. At therapeutic topical concentrations it reduces cohesion between corneocytes and loosens the intercellular material of the stratum corneum, causing controlled desquamation. It also has anti-inflammatory and comedolytic effects. In warts, the main benefit is mechanical removal of keratinised epidermal cells that contain wart virus; it does not sterilise the virus or guarantee that recurrence will not occur.

Absorption rises when the concentration is high, the skin is inflamed or broken, the surface area is large, the product is covered by occlusion, or the patient is a young child. This is why a 2% acne preparation and a 27.5% wart paint must never be treated as interchangeable medicines.

Concentration, formulation and common use

Indications

• Acne vulgaris: helps remove follicular plugs and reduce comedones, especially when mild.
• Psoriasis and seborrhoeic dermatitis: removes adherent scale so an anti-inflammatory or antifungal can reach the skin.
• Ichthyoses and keratodermas: reduces excessive scale, usually with a moisturiser or urea-based product.
• Keratosis pilaris: can smooth follicular roughness, although urea or lactic acid may be better tolerated over large areas.
• Corns and calluses: softens focal pressure-related keratin while pressure and footwear are corrected.
• Common and plantar warts: repeated local application removes infected keratinised tissue. A wart that is atypical, bleeding, pigmented or resistant needs review.

How to apply safely

Contraindications and precautions

• Hypersensitivity to salicylates or the formulation.
• Do not apply to eyes, lips, mucous membranes, deep fissures, open wounds, acutely inflamed or infected skin unless a clinician specifically directs it.
• High-strength wart products should not be used by people with diabetes or impaired circulation on the feet because unnoticed burns may become infected or fail to heal.
• Licensed 6% products are contraindicated in children under 2 years; large-area use in children under 12 requires extra caution and close monitoring.
• Avoid large body-surface application, tight occlusion or multiple salicylate-containing products in renal or hepatic impairment.
• In children or teenagers with influenza or varicella, avoid salicylate exposure unless directed by a physician because of the theoretical Reye syndrome concern.
• Pregnancy and breastfeeding require a risk-benefit decision for extensive or high-concentration treatment. Do not apply to the breast where an infant could ingest residue.

Adverse effects and salicylism

Local effects include stinging, dryness, erythema, peeling, irritant dermatitis, fissuring and chemical burns. Systemic salicylate toxicity is uncommon but dangerous when a strong preparation is spread over large inflamed areas or used excessively.

In confirmed salicylate toxicity, intravenous fluids and urine alkalinisation with sodium bicarbonate may be used under toxicology guidance; severe cases may require haemodialysis. Do not wait for the serum level if the clinical picture is severe.

Important interactions

• Systemic salicylate exposure can compete for albumin binding and may potentiate sulfonylurea hypoglycaemia, methotrexate toxicity and bleeding with oral anticoagulants.
• Use caution with aspirin, bismuth subsalicylate, salicylate-containing sports creams and other salicylates.
• Combining salicylic acid with tretinoin, benzoyl peroxide, sulfur, resorcinol, strong alcohol-based products or abrasive scrubs increases irritation. Introduce one active agent at a time.
• With topical corticosteroids, the combination can be useful for a thick psoriatic plaque but should be limited to the affected area and reviewed for steroid overuse.

4. Urea

Mechanism and concentration-dependent action

Urea is a natural moisturising-factor component made synthetically for topical products. At low strength it attracts and retains water in the stratum corneum. At medium and high strengths it disrupts the intracellular matrix between corneocytes, loosens the horny layer and increases desquamation. It can also improve penetration of corticosteroids, antifungals and other topical medicines.

Indications and dosing examples

• Urea 20% cream: apply to affected skin twice daily, rub in until absorbed; products may be used for xerosis, dermatitis, psoriasis, ichthyosis, keratosis pilaris, keratoderma, corns, calluses and damaged or devitalised nails.
• Urea 40% cream: apply to the localised hyperkeratotic skin or diseased nail twice daily, or as directed. A clinician may use occlusion for a short period when treating a thick nail, but the patient must not extend occlusion to large areas.
• Urea 39.5% plus salicylic acid 2%: a prescription keratolytic-emollient combination may be applied to affected skin or nails twice daily; stop if marked irritation occurs.
• Use a lower strength on the face, genital area, fissured eczema or large body surface. Applying after bathing while the skin is slightly damp can improve hydration, but very wet skin may increase stinging.

Adverse effects, contraindications and interactions

• Transient stinging, burning, itching, erythema, irritation or contact dermatitis; high-strength products sting more on fissures and erosions.
• Hypersensitivity to urea or excipients is a contraindication. Avoid eyes, lips, mucosa, open wounds and actively infected tissue unless specifically directed.
• There are no important systemic drug interactions expected from ordinary topical use, but urea can increase penetration of another topical drug. Reassess the potency and amount of a corticosteroid or antifungal used beneath it.
• Pregnancy and breastfeeding data are limited. Small-area use is generally considered low risk, but extensive high-strength treatment should be clinician-directed; do not apply to the nipple before feeding.

5. Propylene glycol

Propylene glycol is a hygroscopic vehicle and humectant with keratolytic activity. It attracts water, improves hydration and can alter the compacted stratum corneum so that scale is released. It is especially useful in some inherited or acquired ichthyoses and in hyperkeratotic plaques when formulated at a high concentration.

Clinical use

• Compounded propylene glycol preparations, often approximately 40–60% in an aqueous or gel base, have been used under specialist direction for ichthyosis, palmoplantar keratoderma and thick scale. There is no single universal strength or dosing schedule; prescribe according to the formulation and local dermatology protocol.
• Apply a thin film to affected areas once or twice daily, often after bathing. Short-term occlusion may increase response but also increases irritation and absorption.
• Because it is also a solvent and preservative, propylene glycol may cause irritant or allergic contact dermatitis, particularly on inflamed skin.

Safety

• Do not apply to eyes, mucosa, deep erosions or extensive broken skin without specialist advice.
• Stop if burning, eczema-like rash or worsening inflammation develops. Consider an alternative humectant such as urea or glycerol if contact allergy is suspected.
• It can increase penetration of medicines mixed in the same vehicle; document the complete compounded formula and avoid accidental steroid overexposure.

6. Benzoyl peroxide

Why it appears in a keratolytic lesson

Benzoyl peroxide is primarily an oxidising antimicrobial and acne medicine, but the supplied deck correctly includes its mild keratolytic and desquamating effects. It releases oxygen free radicals that reduce Cutibacterium acnes and can loosen follicular debris. Unlike an antibiotic, bacterial resistance to benzoyl peroxide is not a major clinical problem.

Strengths, indications and dosing

Adverse effects and precautions

• Dryness, erythema, burning, itching, peeling, swelling, irritant dermatitis and rarely allergic contact dermatitis or severe hypersensitivity.
• It bleaches hair, towels, clothing and dyed fabrics. Warn the patient before use.
• Avoid eyes, lips, mucosa, eczema and freshly abraded skin. Use sunscreen and reduce frequency to every other day if excessive peeling occurs.
• Do not swallow. Accidental ingestion requires poison-centre advice.
• Combining benzoyl peroxide with tretinoin, salicylic acid, sulfur, resorcinol, abrasive cleansers or strong alcohol products can cause severe irritation. If both tretinoin and benzoyl peroxide are prescribed, they may be separated by time of day or a compatible formulation selected.

7. Tretinoin

Mechanism of action

Tretinoin is all-trans-retinoic acid. Topically it reduces cohesion of follicular epithelial cells, decreases microcomedone formation and increases turnover so existing comedones are extruded. It is therefore a comedolytic retinoid rather than a conventional scale-dissolving acid.

Strengths and dose

Use enough to cover the entire affected area lightly, not a thick layer on individual spots. Therapeutic improvement may begin after two to three weeks, while a definite response may require six weeks or longer. A temporary early increase in visible lesions can reflect previously developing microcomedones becoming apparent, but marked swelling, blistering or crusting is not an expected “purge” and needs review.

Indications and limits

• Licensed topical indication: acne vulgaris, especially comedonal acne and mixed acne.
• Specialists may use retinoids for selected keratinisation disorders or keratosis pilaris, but long-term safety and efficacy outside the labelled indication vary by product and patient.
• It is not a treatment for bacterial impetigo, fungal infection or an undiagnosed pigmented lesion.

Adverse effects and interactions

• Warmth or stinging, dryness, erythema, scaling, peeling, photosensitivity, irritant dermatitis and temporary pigment change.
• Severe irritation is more likely on eczema, sunburn, windburn or recently shaved/abraded skin. Pause or reduce frequency until the barrier recovers.
• Minimise sunlight and avoid sunlamps; use protective clothing and sunscreen.
• Use caution with salicylic acid, benzoyl peroxide, sulfur, resorcinol, abrasive soaps, alcohol-based astringents and other drying agents. Introduce them at separate times only when the regimen is deliberately planned.
• Pregnancy planning and pregnancy require clinician review. Do not advise unsupervised topical or oral retinoid use during pregnancy; oral retinoids are strongly teratogenic, and topical products should be stopped if pregnancy occurs unless a specialist gives a different plan.
• Contraindication: hypersensitivity to the product ingredients. Avoid eyes, mouth, nasal angles and mucous membranes.

8. Podophyllin resin and podofilox: destructive wart medicines

Podofilox/podophyllotoxin 0.5%

Purified podofilox inhibits microtubule assembly and arrests mitosis, producing necrosis of visible external anogenital wart tissue. It is not for internal vaginal, cervical, urethral, rectal or other mucosal warts and does not treat invasive cancer.

• Adult regimen: apply 0.5% solution with the supplied applicator or 0.5% gel with a finger twice daily, morning and evening, for three consecutive days; then use no treatment for four consecutive days. This is one treatment week and may be repeated for up to four cycles.
• Maximum exposure: treat no more than 10 cm² of wart tissue and do not exceed 0.5 mL per day.
• Technique: apply only to visible warts identified by a clinician; keep off normal skin; allow to dry; wash hands; avoid sexual contact while medicine is present.
• Adverse effects: burning, pain, erythema, swelling, soreness, erosion, ulceration, itching and bleeding. Stop and seek review for severe pain, swelling, bleeding or extensive ulceration.
• Contraindications: hypersensitivity, pregnancy, uncertain diagnosis, mucosal or internal lesions, and use beyond the prescribed area or cycles.

Podophyllin resin 10–25%

Crude podophyllin resin in a compound tincture of benzoin is an older provider-applied treatment. Where it is still used and no safer option is available, a trained clinician applies a small amount to external warts, protects surrounding skin, allows it to dry and washes it off after the locally recommended contact time, commonly 1–4 hours. Treatment is generally no more than once weekly and must respect strict surface-area and volume limits.

• Never use on pregnancy, mucous membranes, cervix, vagina, urethra, anus, large areas, bleeding lesions or suspected cancer.
• Do not confuse podophyllin resin with podofilox 0.5%; their concentrations, purity and application protocols are different.
• Systemic toxicity can include vomiting, abdominal pain, diarrhoea, neuropathy, confusion, seizures, marrow suppression, kidney injury and multi-organ failure. Accidental ingestion or extensive exposure requires emergency toxicology advice.

Historical oral-medicine note: hairy tongue

The supplied deck mentions a 1% podophyllin solution and topical tretinoin for hairy tongue caused by defective desquamation and elongation of filiform papillae. This is a historical teaching point, not an invitation to self-treat the mouth with podophyllin. Current assessment should look for smoking, poor oral hygiene, antibiotics, xerostomia, bismuth, diet and candidiasis; management usually involves tongue brushing or scraping, removal of triggers and treatment of an identified infection. Refer persistent, painful, pigmented or ulcerated oral lesions.

9. Additional keratolytic options used in practice

10. Choosing a keratolytic by skin condition

11. Safe application technique

1. Confirm the target: document diagnosis, site, size, extent, skin integrity, sensation and circulation. Do not acid-treat a lesion that might be melanoma, squamous-cell carcinoma, infected eczema or a pressure ulcer.
2. Clean gently: use water or a mild cleanser; avoid abrasive scrubbing. Pat dry.
3. Protect normal skin: apply petrolatum around a wart or corn when using a concentrated product. Do not allow solution to pool in skin folds.
4. Use a thin film: more product does not mean faster treatment. Use the smallest amount that covers the affected area.
5. Respect contact time: a shampoo is rinsed; a nightly 6% cream may be washed in the morning; podofilox follows a three-days-on/four-days-off cycle; do not invent an occlusion period.
6. Moisturise: use a bland, fragrance-free emollient after the active treatment or at a different time of day when appropriate.
7. Wash hands: unless the hands are the treatment site. Keep products away from children and label compounded preparations clearly.
8. Review: assess response, irritation, adherence, new lesions and whether the diagnosis remains correct.

Using a keratolytic with a topical steroid

On a thick psoriatic or eczematous plaque, a keratolytic can be used before or with a topical corticosteroid to improve penetration. The steroid strength, surface area, duration and occlusion must be deliberately chosen. Warn the student that “more penetration” also means more steroid adverse effects: atrophy, striae, telangiectasia, infection and, with extensive use, systemic absorption. Do not use keratolysis to justify prolonged high-potency steroid use on the face, groin or flexures.

12. Monitoring checklist

13. Emergency presentations related to keratolytics

Suspected salicylate toxicity

• Stop all topical salicylates and remove contaminated clothing.
• Assess airway, breathing, circulation, mental state, temperature and glucose.
• Ask about the product strength, amount, body surface area, occlusion, age, kidney/liver disease and oral salicylates.
• Check electrolytes, blood gas, renal function and salicylate concentration; serial levels may be needed because absorption can continue.
• Urgently involve toxicology for altered mental state, acidosis, pulmonary oedema, renal failure, seizures or rising levels. Sodium bicarbonate alkalinisation and haemodialysis are specialist treatments.

Chemical burn or eye exposure

• Remove contact lenses and irrigate the eye immediately with copious clean water or saline for at least 15 minutes; arrange urgent ophthalmic assessment.
• For skin exposure, remove contaminated clothing and irrigate. Do not neutralise an acid with another chemical.
• Assess burn depth, surface area, pain, infection and function. Face, hands, genitalia, circumferential lesions and large-area burns require referral.

Podophyllin or podofilox overexposure

• Stop the product and wash the affected area gently. Do not apply additional acids or occlusion.
• Look for severe local pain, ulceration, vomiting, diarrhoea, neuropathy, weakness, confusion, seizures, marrow suppression or renal injury.
• Contact a poison centre or toxicologist. Bring the bottle or photograph the label because podophyllin resin and podofilox are not equivalent.

Immediate hypersensitivity

Facial swelling, wheeze, widespread urticaria, dizziness or collapse after benzoyl peroxide, propylene glycol, urea or a vehicle ingredient requires emergency anaphylaxis treatment according to local protocol. Mild local redness alone is more often irritant dermatitis, but rapidly progressive swelling should not be dismissed.

14. Clinical cases for emergency-medicine students

15. High-yield examination points

• Salicylic acid is the classic beta-hydroxy keratolytic; dose, concentration, surface area and occlusion determine toxicity.
• Urea is a humectant at low concentration and a keratolytic at higher concentration; 20–40% products soften thick skin and nails.
• Benzoyl peroxide is mainly an oxidising antimicrobial for acne, with additional mild keratolytic action.
• Tretinoin is a comedolytic retinoid that normalises follicular keratinisation; use a thin film once nightly and expect irritation if introduced too quickly.
• Podophyllin/podofilox destroy wart tissue by antimitotic cytotoxicity; they are not interchangeable and require strict surface and duration limits.
• Do not apply concentrated acids to diabetic, neuropathic or poorly perfused feet without assessment.
• Do not treat atypical, bleeding, pigmented, facial or mucosal lesions as ordinary warts.
• For thick inflammatory plaques, keratolysis is an adjunct; it does not replace treatment of psoriasis, eczema, infection or malignancy.
• When several topical actives are combined, irritation and absorption rise faster than benefit. Start one active at a time.
• Emergency red flags are salicylate toxicity, eye exposure, chemical burn, anaphylaxis, extensive ulceration and systemic podophyllin symptoms.

16. Sources and further study

• Supplied SlideShare: Topical keratolytics and topical steroids
• DailyMed: Salicylic Acid 6% cream
• DailyMed: Salicylic Acid 27.5% wart remover
• DailyMed: Urea 20% cream
• DailyMed: Urea 40% cream
• DailyMed: Benzoyl peroxide topical wash
• DailyMed: Tretinoin cream
• DailyMed: Ammonium lactate 12% lotion
• DailyMed: Podofilox 0.5% solution
• CDC STI Treatment Guidelines: anogenital warts
• Urea in dermatology: review of moisturising, keratolytic and barrier effects